Sign in
Taking peopleNo phase

Testing the SAPIEN X4 heart valve in people with severe aortic stenosis

Tests the SAPIEN X4 replacement heart valve in people with symptomatic severe aortic stenosis.

Key facts

Who runs it
Edwards Lifesciences
Where
Christchurch, New ZealandSee the siteAlso in 3 other countries, 64 sites
Trial code
Registry title
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
Status
Recruiting
People taking part
1,234 people, planned
Started
20 Jun 2022
Expected to end
Jan 2037
Type of study
Interventional, 3 groups
Treatments tested
  • SAPIEN X4 THV
  • SAPIEN X4S
Record updated
24 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with severe, calcified narrowing of the aortic heart valve (aortic stenosis) that causes symptoms. They will get the SAPIEN X4 or X4S valve through a catheter.

Sex
All sexes can join.
Disease stage
Severe, calcified aortic stenosis. Heart failure symptoms of NYHA class II or higher. The size of the valve ring must fit the SAPIEN X4 valve.
Earlier treatment
People who already have a mechanical or tissue heart valve in any position cannot join. People who had any surgery or catheter procedure within 30 days before cannot join, unless it is part of the planned treatment of coronary artery disease. A pacemaker or ICD is allowed.

Main reasons for not taking part

  • Aortic valve with one or two leaflets (unicuspid, bicuspid) or without calcium
  • Left ventricular ejection fraction < 20%, or heart attack within 30 days
  • Stroke or TIA within 90 days, or endocarditis within 180 days
  • Kidney failure or being on dialysis or other kidney replacement therapy
  • Pregnancy or breastfeeding, BMI > 50 kg/m2, or life expectancy < 24 months

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Severe, calcific AS
  • Native aortic annulus size suitable for SAPIEN X4 THV
  • NYHA functional class ≥ II
  • The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent

Who cannot take part

  • Myocardial infarction within 30 days prior to the study procedure
  • Subjects with planned concomitant ablation for atrial fibrillation
  • Any surgical or transcatheter procedure within 30 days prior to the study procedure (unless part of planned strategy for treatment of CAD). Implantation of a permanent pacemaker or implantable cardioverter defibrillator (ICD) is not considered an exclusion
  • Any planned surgical or transcatheter intervention to be performed within 30 days following the study procedure (unless part of planned strategy for treatment of CAD)
  • Endocarditis within 180 days prior to the study procedure
  • Stroke, transient ischemic attack or neurological signs and symptoms attributed to carotid or vertebrobasilar disease within 90 days prior to the study procedure
  • Hemodynamic or respiratory instability requiring inotropic or mechanical support within 30 days prior to the study procedure
  • Inability to tolerate or condition precluding treatment with antithrombotic therapy
  • Absolute contraindications or allergy to iodinated contrast that cannot be adequately treated with premedication
  • Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
  • Participating in another investigational drug or device study that has not reached its primary endpoint
  • Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
  • Complex coronary artery disease (CAD) that cannot be optimally treated by percutaneous coronary intervention (PCI)
  • Renal insufficiency and/or renal replacement therapy
  • Hypercoagulable state or other condition that increases risk of thrombosis
  • Left ventricular ejection fraction < 20%
  • Anatomical characteristics that would preclude safe femoral placement of the introducer sheath or safe passage of the delivery system
  • Aortic valve is unicuspid, bicuspid or non-calcified
  • Pre-existing mechanical or bioprosthetic valve in any position
  • Severe aortic regurgitation (> 3+)
  • Severe mitral regurgitation (> 3+) or ≥ moderate mitral stenosis
  • Need for mitral, tricuspid or pulmonic valve intervention within the next 12 months
  • Left ventricular outflow tract calcification that would increase the risk of annular rupture or significant PVL after THV implantation
  • Increased risk of coronary artery obstruction after THV implantation
  • Hypertrophic cardiomyopathy with subvalvular obstruction
  • Leukopenia, anemia, thrombocytopenia
  • Subject refuses blood products
  • BMI > 50 kg/m2
  • Estimated life expectancy < 24 months
  • Female who is pregnant or lactating
  • Subject considered to be part of a vulnerable population

Where in New Zealand

Also in 3 other countries, 64 sites

  • Christchurch HospitalChristchurch, New ZealandContact: Edwards THV Clinical AffairsNo longer taking part

About the trial

What the trial wants to find out

The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4/X4S Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS).

The 3 groups in the trial

  • TAVR - Main CohortTreatment being tested

    Subjects will undergo transcatheter aortic valve replacement (TAVR)

    Treatment: SAPIEN X4 THV

  • TAVR - Bicuspid RegistryTreatment being tested

    Subjects with bicuspid aortic valve morphology will undergo TAVR

    Treatment: SAPIEN X4 THV

  • TAVR - X4S RegistryTreatment being tested

    Subjects will undergo transcatheter aortic valve replacement (TAVR)

    Treatment: SAPIEN X4S

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve
Plain-language title
Testing the SAPIEN X4 heart valve in people with severe aortic stenosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
24 September 2026